VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NRCNational Research Corporation
$20.81$469M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksNRCFinancials

National Research Corporation (NRC) Financials

30Y historyFree accessUpdated daily

Gross margins have trended downward from 63.7% in 2023Q4 to 54.6% in 2026Q1, indicating potential loss of pricing power and ineffective management of fixed costs.

NRC Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue138.64M137.39M143.06M148.58M151.57M147.95M133.28M127.98M119.69M117.56M109.38M102.34M98.84M92.59M86.42M75.77M63.4M57.69M51.01M48.92M43.77M32.44M29.68M26.92M22.39M17.67M18.32M18.2M17.7M16.3M12.6M
Revenue Growth %-1.88%-3.96%-3.72%-1.97%2.44%11.01%4.14%6.93%1.81%7.47%6.88%3.55%6.75%7.14%14.06%19.51%9.89%13.09%4.27%11.77%34.95%9.27%10.26%20.26%26.67%-3.51%0.64%2.82%8.59%29.37%-
Cost of Goods Sold61.21M59.99M56.93M56.02M57.05M52.35M49.19M46.44M47.58M49.07M45.58M44.61M41.72M38.84M35.46M28.67M24.64M24.57M23.61M21.8M19.45M13.64M12.87M12.03M9.56M8.06M9.12M11.1M9.4M7.2M5.7M
COGS % of Revenue-43.67%39.8%37.7%37.64%35.38%36.91%36.28%39.75%41.74%41.67%43.59%42.21%41.95%41.03%37.84%38.86%42.6%46.28%44.56%44.43%42.06%43.36%44.68%42.68%45.6%49.79%60.99%53.11%44.17%45.24%
Gross Profit77.43M77.39M86.13M92.56M94.52M95.6M84.09M81.55M72.11M68.49M63.81M57.73M57.12M53.75M50.96M47.1M38.76M33.12M27.4M27.12M24.33M18.79M16.81M14.89M12.83M9.61M9.2M7.1M8.3M9.1M6.9M
Gross Margin %55.85%56.33%60.2%62.3%62.36%64.62%63.09%63.72%60.25%58.26%58.33%56.41%57.79%58.05%58.97%62.16%61.14%57.4%53.72%55.44%55.57%57.94%56.64%55.32%57.32%54.4%50.21%39.01%46.89%55.83%54.76%
Gross Profit Growth %--10.14%-6.96%-2.07%-1.13%13.69%3.12%13.09%5.28%7.34%10.52%1.08%6.27%5.47%8.2%21.51%17.05%20.86%1.03%11.5%29.43%11.78%12.9%16.06%33.46%4.55%29.53%-14.46%-8.79%31.88%-
Operating Expenses57.87M54.8M50.93M52.52M47.98M45.33M41.41M38.51M36.83M34.27M32.61M31.29M28.82M28.94M28.24M28.36M24.91M19.42M15.41M15.76M14.42M10.38M9.41M7.93M6.41M6.9M5.87M5M5.2M4.2M3.3M
OpEx % of Revenue-39.89%35.6%35.35%31.65%30.64%31.07%30.09%30.78%29.15%29.81%30.57%29.16%31.26%32.68%37.44%39.29%33.66%30.21%32.21%32.94%32%31.71%29.45%28.64%39.05%32.06%27.47%29.38%25.77%26.19%
Selling, General & Admin57.87M54.8M44.91M46.58M42.7M38.96M34.44M32.97M31.37M29.69M28.39M27.18M25.02M25.21M23.54M23.3M20.2M15.59M12.73M13.17M12.16M8.62M7.39M5.99M4.74M4.99M4.6M4.2M4.8M4M3.1M
SG&A % of Revenue-39.89%31.39%31.35%28.17%26.33%25.84%25.76%26.21%25.25%25.95%26.55%25.31%27.23%27.24%30.75%31.87%27.02%24.95%26.93%27.78%26.57%24.91%22.24%21.16%28.21%25.13%23.08%27.12%24.54%24.6%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses006.02M5.94M5.28M6.37M7.03M5.54M885K50K302K1.07M18K16K-3K5.07M4.7M3.83M2.69M2.58M2.26M1.76M2.02M1.94M1.67M1.92M1.27M800K400K200K200K
Operating Income19.56M22.59M35.19M40.05M46.54M50.27M42.68M43.03M35.27M34.22M31.2M26.45M28.3M24.81M22.72M18.73M13.86M13.7M11.99M11.37M9.91M8.41M7.4M6.96M6.42M2.71M3.32M2.1M3.1M4.9M3.6M
Operating Margin %14.11%16.44%24.6%26.95%30.71%33.98%32.02%33.63%29.47%29.11%28.52%25.84%28.63%26.79%26.29%24.73%21.86%23.74%23.5%23.23%22.64%25.94%24.94%25.87%28.67%15.35%18.15%11.54%17.51%30.06%28.57%
Operating Income Growth %--35.81%-12.11%-13.96%-7.41%17.79%-0.83%22%3.09%9.69%17.96%-6.53%14.07%9.19%21.27%35.2%1.17%14.25%5.49%14.71%17.74%13.69%6.27%8.51%136.64%-18.41%58.31%-32.26%-36.73%36.11%-
EBITDA27.81M30.21M41.22M45.94M51.82M56.64M50.18M48.57M40.74M38.8M35.42M30.56M32.1M28.54M27.42M23.8M18.56M17.53M14.67M13.95M12.17M10.18M9.42M8.91M8.09M4.63M4.59M2.9M3.5M5.1M3.8M
EBITDA Margin %20.06%21.99%28.81%30.92%34.19%38.28%37.65%37.95%34.04%33.01%32.38%29.86%32.48%30.82%31.73%31.41%29.28%30.38%28.77%28.51%27.8%31.38%31.73%33.08%36.15%26.19%25.08%15.93%19.77%31.29%30.16%
EBITDA Growth %-32.4%-26.69%-10.29%-11.34%-8.52%12.88%3.31%19.24%4.98%9.55%15.92%-4.81%12.48%4.08%15.2%28.23%5.89%19.45%5.2%14.64%19.56%8.04%5.76%10.03%74.84%0.76%58.42%-17.14%-31.37%34.21%-
D&A (Non-Cash Add-back)8.25M7.62M6.02M5.9M5.28M6.37M7.5M5.54M5.46M4.59M4.22M4.11M3.8M3.73M4.7M5.07M4.7M3.83M2.69M2.58M2.26M1.76M2.02M1.94M1.67M1.92M1.27M800K400K200K200K
EBIT19.55M22.61M35.28M40.09M44.02M50.29M43.28M43.03M35.27M34.22M31.2M26.45M28.4M24.81M22.75M18.79M13.81M13.52M12.12M11.37M9.91M8.42M7.4M6.96M6.42M2.71M3.32M2.1M3.1M4.9M3.6M
Net Interest Income-4.99M-4.65M-2.47M-42K-1.04M-1.65M-1.79M-2.05M-1.45M14K-143K-160K-222K-334K-509K-616K-485K-403K-97K000000000000
Interest Income127K111K125K820K168K14K18K37K62K96K47K60K83K63K32K13K6K2K42K000000000000
Interest Expense5.12M4.76M2.6M862K1.21M1.67M1.81M2.09M1.51M82K190K220K305K397K541K629K491K405K139K000000000000
Other Income/Expense-5.06M-4.75M-2.5M-83K-3.73M-1.65M-1.21M-2.52M-566K64K159K913K-204K-318K-512K-575K-542K-580K-6K-248.16K-402.1K99K-118.79K-49K-257.64K-88.57K531.54K100K-2.3M-1.3M200K
Pretax Income14.5M17.84M32.69M39.96M42.81M48.62M41.47M40.52M34.71M34.28M31.36M27.36M28.09M24.49M22.21M18.16M13.31M13.12M11.98M11.12M9.51M8.51M7.28M6.92M6.16M2.62M3.86M2.2M800K3.6M3.8M
Pretax Margin %10.46%12.99%22.85%26.9%28.25%32.86%31.11%31.66%29%29.16%28.67%26.73%28.42%26.45%25.7%23.97%21%22.74%23.49%22.72%21.72%26.25%24.54%25.69%27.52%14.85%21.05%12.09%4.52%22.09%30.16%
Income Tax5.47M6.24M7.91M8.99M11.02M11.15M4.21M8.11M4.66M11.34M10.84M9.75M9.94M9M7.14M6.6M4.82M4.63M4.54M4.28M3.62M3.28M2.73M2.53M2.31M953.63K1.14M700K300K400K1.5M
Effective Tax Rate %37.7%34.99%24.19%22.5%25.73%22.94%10.15%20.02%13.43%33.08%34.56%35.64%35.37%36.77%32.15%36.32%36.17%35.27%37.87%38.48%38.1%38.5%37.52%36.61%37.51%36.34%29.55%31.82%37.5%11.11%39.47%
Net Income9.03M11.6M24.78M30.97M31.8M37.47M37.26M32.41M30.05M22.94M20.52M17.61M18.16M15.48M15.07M11.56M8.5M8.49M7.45M6.84M5.88M5.24M4.55M4.38M3.85M1.67M2.72M1.5M500K3.2M2.3M
Net Margin %6.52%8.44%17.32%20.84%20.98%25.32%27.96%25.32%25.1%19.52%18.76%17.21%18.37%16.72%17.44%15.26%13.41%14.72%14.59%13.98%13.44%16.14%15.33%16.28%17.2%9.45%14.83%8.24%2.82%19.63%18.25%
Net Income Growth %-62.68%-53.19%-19.98%-2.61%-15.12%0.55%14.98%7.85%30.96%11.82%16.51%-3.01%17.26%2.76%30.3%36.06%0.09%14.05%8.86%16.23%12.38%15.06%3.8%13.87%130.5%-38.52%81.12%200%-84.38%39.13%-
Net Income (Continuing)9.04M11.6M24.78M30.97M31.8M37.47M37.26M32.41M30.05M22.94M20.52M17.61M18.16M15.48M15.07M11.56M8.5M8.49M7.45M6.84M5.88M5.24M4.55M4.38M3.85M1.67M2.72M1.5M500K3.2M2.3M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)0.410.521.041.251.271.461.451.261.070.520.480.410.430.372.171.691.261.261.090.980.850.740.630.600.540.240.390.210.060.370.37
EPS Growth %-61.39%-50%-16.8%-1.57%-13.01%0.69%15.08%17.76%105.77%8.33%17.07%-4.65%16.22%-82.95%28.4%34.13%0%15.6%11.22%15.29%14.86%17.46%5%11.11%125%-38.46%85.71%250%-83.78%0%-
EPS (Basic)-0.521.051.261.281.471.481.301.110.540.490.420.440.372.221.731.281.281.111.000.860.740.630.600.540.240.390.210.060.370.37
Diluted Shares Outstanding21.91M22.4M23.74M24.67M25.05M25.64M25.7M25.65M28.08M25.23M24.6M24.5M24.61M24.61M6.95M6.84M6.74M6.72M6.83M6.98M6.92M7.08M7.28M7.31M7.16M7.09M7.06M7.5M8.33M8.65M6.22M
Basic Shares Outstanding21.8M22.38M23.72M24.54M24.92M25.42M25.17M24.81M27.09M24.28M24.22M24.22M24.24M24.12M6.78M6.67M6.64M6.64M6.68M6.84M6.84M7.08M7.22M7.31M7.13M6.96M6.97M7.14M8.33M8.65M6.22M
Dividend Payout Ratio-94.64%46.21%117.42%65.92%24.45%28.23%96.58%56.11%73.52%139.16%57.09%-13.83%115.23%51.12%59.55%50.21%50.65%48.6%46.84%43.13%-------137.5%143.48%

Key Metrics

Growth RegimeContracting
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowDeteriorating
Top Statement Risk

Competitive Disintermediation Risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Persistent Revenue Contraction Trends

As reported in recent financial filings, NRC has experienced a sustained period of negative year-over-year revenue growth, with the most recent quarter showing a 3.7% increase that fails to offset the broader trend of contraction observed over the preceding eight quarters of data.

The inability to maintain consistent top-line expansion suggests that the company's core subscription model may be facing significant headwinds from market saturation or competitive poaching. Investors should monitor whether this stagnation reflects a temporary cyclical trough or a more permanent erosion of the company's value proposition within the healthcare information services sector.

Structural Margin Compression Risks

Based on the provided income statement data, NRC's gross margin has trended downward from a peak of 63.7% in 2023Q4 to 54.6% in 2026Q1, indicating a potential loss of pricing power or rising costs associated with maintaining its proprietary data analytics platform.

This contraction in gross profitability appears to be compounded by volatility in operating margins, which have fluctuated significantly as the company struggles to scale its cost base against declining revenue. Such margin instability warrants further investigation into whether the firm is being forced to increase service intensity to retain existing clients.

Operating Leverage Under Significant Pressure

According to the historical income statement, NRC's operating income has demonstrated high sensitivity to revenue fluctuations, with operating margins compressing from 30.8% in 2023Q4 to 16.0% in 2026Q1, suggesting that fixed costs are not being managed effectively during this period of top-line weakness.

The lack of operating leverage implies that the company's cost structure remains heavily weighted toward fixed expenditures that do not adjust downward in tandem with revenue. This dynamic creates a precarious environment where even minor further declines in contract volume could lead to disproportionate impacts on bottom-line profitability.

Earnings Quality Impacted by SBC

Based on the reported figures, NRC's net income has faced significant volatility, with stock-based compensation expenses rising to $1.6M in 2026Q1, which appears to be a material drag on earnings quality compared to the lower compensation levels observed in previous fiscal periods.

The rising trend in stock-based compensation, coupled with the recent net income decline, suggests that shareholders are experiencing dilution while the underlying operational performance remains stagnant. Analysts should scrutinize whether these compensation levels are tied to performance metrics that are currently misaligned with the company's actual growth trajectory.

Disintermediation Threatens Long-term Viability

While the company maintains a proprietary database, the risk of EHR giants integrating native feedback loops, as suggested by industry trends, poses a fundamental threat to NRC's business model that may not be fully captured by current valuation multiples or historical benchmarking data.

Short-sellers would likely focus on the potential for NRC's core services to be commoditized by larger, integrated healthcare platforms that offer survey tools as a bundled feature. If the market shifts toward these integrated solutions, NRC's historical data moat may prove insufficient to prevent a permanent decline in its competitive standing.

NRC — Frequently Asked Questions

Quick answers to the most common questions about buying NRC stock.

What was National Research Corporation's (NRC) revenue in 2025?

For fiscal year 2025, National Research Corporation (NRC) reported total revenue of $137.4M. This represents a 990.4% increase compared to $12.6M in 1996.

Is National Research Corporation (NRC) profitable?

National Research Corporation (NRC) is profitable, generating $11.6M in net income for the fiscal year ending 2025 with a net profit margin of 8.4%.

What is National Research Corporation's operating profit margin?

National Research Corporation (NRC) reported an operating income of $22.6M, resulting in an operating profit margin of 16.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is National Research Corporation's gross profit and gross margin?

National Research Corporation (NRC) generated $77.4M in gross profit for the year, representing a gross profit margin of 56.3%. This demonstrates the company's core pricing power and production efficiency.